Augmentin :: Multiple pharmacies comparison.

LYON, France — Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
GlaxoSmithKline plc company profile
To order that report:
www.reportlinker.com/p064471/GlaxoSmithKline- plc-PharmaVitae-Profile.html
(Due to its length, this URL may need to be copied/pasted into your Internet browser’s address field. Remove the extra space if one exists.)
Introduction
This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
Cross Cultural Management In The Age Of Globalization
Today’s Best Part-Time Jobs
10 Jobs That Pay $30 An Hour
Time Management: Stop Procrastination Today

Scope
Highlights
Reasons to Purchase
Benchmark GlaxoSmithKline’s performance against key rivals in the ethical pharmaceutical sectorAnalyze the factors that will underscore a forecast ethical pharmaceutical sales CAGR of -2.1% for GlaxoSmithKline over 2006-12Assess the generic threat faced by GlaxoSmithKline over the period 2006-12 and how this compares to generic risk across the Big Pharma peer set
CHAPTER 1 EXECUTIVE SUMMARY 2
Key findings 2
Historical and forecast ethical sales performance 3
Therapeutic strategy 5
Launch and expiry outlook 10
Externalization, geographic and molecule type strategies 13
Externalization strategy 14
Geographic strategy 15
Molecule type strategy 16
SWOT analysis 17
Strengths 17
Weaknesses 18
Opportunities 19
Threats 21
CHAPTER 2 CORPORATE HISTORY 24
Key findings 24
Background 25
M&A history 25
Wellcome 25
Glaxo 25
Glaxo Wellcome 26
Beecham 26
Smith Kline 26
SmithKline Beecham 27
Key historical drug launches by component GSK companies 28
M&A strategy 29
R&D overview 32
Current corporate structure 34
CHAPTER 3 HISTORICAL PERFORMANCE 35
Key findings 35
Introduction 36
Revenue and growth rate analysis, 2001-06 36
Revenue and growth rate vs. peer set 37
Product analysis, 2001-06 39
Growth drivers 39
Seretide/Advair 39
Avandia 40
Flixotide 40
Lamictal 40
Growth resistors 40
Seroxat 40
Augmentin 41
Serevent 41
Operating revenue and cost analysis, 2001-06 42
Operating revenue/cost analysis 43
CHAPTER 4 FORECAST PERFORMANCE 45
Key findings 45
Introduction 46
Revenue and growth rate, 2006-12 46
Product analysis, 2006-12 48
Growth drivers 53
Tykerb 53
Cervarix 54
Growth resistors 54
Seretide/Advair 54
Avandia 55
Wellbutrin 55
Zofran 56
Imigran 56
Therapy area analysis, 2006-12 58
Oncology 61
Urology & sexual health 61
Infectious disease 62
Respiratory 62
CNS 62
Endocrine, metabolic & genetic disorders 63
Therapy area focus 63
Launches and expiries analysis, 2006-12 68
Launch portfolio 69
Core portfolio 72
Expiry portfolio 74
Launch/core/expiry configuration 77
Externalization analysis, 2006-12 81
Geographic analysis, 2006-12 86
Molecule type analysis, 2006-12 89
CHAPTER 5 KEY PRODUCTS AND COMPETITORS 95
Key findings 95
Overview 96
Respiratory 97
Seretide/Advair 97
Overview 97
Sales forecast 98
Newsflow 98
Oncology 103
Tykerb 103
Overview 103
Sales forecast 104
Newsflow 104
Cervarix 107
Overview 107
Sales forecast 108
Newsflow 108
Zofran 112
Overview 112
Sales forecast 113
Newsflow 113
CNS 115
Lamictal 115
Overview 115
Sales forecast 116
Newsflow 116
Gepirone ER 119
Overview 119
Sales forecast 120
Newsflow 120
Trexima 122
Overview 122
Sales forecast 123
Newsflow 124
Wellbutrin 126
Overview 126
Sales forecast 127
Newsflow 127
Imigran 130
Overview 130
Sales forecast 131
Newsflow 131
Endocrine, metabolic & genetic disorders 133
Avandia 133
Overview 133
Sales forecast 134
Newsflow 135
Infectious disease 139
Rotarix 139
Overview 139
Sales forecast 140
Newsflow 140
CHAPTER 6 APPENDIX 143
IMS vs. company-reported data reconciliation 143
References 146
Datamonitor reports 146
Abbreviations 146
Exchange rates 147
List of Tables
Table 1: Peer set overview 37
Table 2: Operating revenue/cost analysis ($m), 2001-06 42
Table 3: Operating cost ratio analysis (% of total revenues), 2001-06 43
Table 4: Product portfolio overview, sales ($m), 2006-12 48
Table 5: Therapy area overview, sales ($m), 2006-12 58
Table 6: Launch portfolio overview, sales ($m), 2006-12 69
Table 7: Core portfolio overview, sales ($m), 2006-12 73
Table 8: Expiry portfolio overview, sales ($m), 2006-12 75
Table 9: Externally developed portfolio ($m), 2006-12 81
Table 10: Molecule type overview, sales ($m), 2006-12 89
Table 11: Key products overview 96
Table 12: Seretide/Advair: overview 97
Table 13: Seretide/Advair: sales forecast ($m), 2006-12 98
Table 14: Seretide/Advair: news flow 98
Table 15: Tykerb: overview 103
Table 16: Tykerb: sales forecast ($m), 2006-12 104
Table 17: Tykerb: news flow 104
Table 18: Cervarix: overview 107